GLP-1R 16mg

GLP-1R 16mg

$303.00

Retatrutide (LY3437943) is a groundbreaking synthetic peptide that functions as a triple agonist, simultaneously targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). By mimicking the effects of three key hormones involved in metabolic regulation and appetite control, Retatrutide offers a comprehensive approach to weight loss and metabolic health. This unique mechanism positions it as a promising candidate for the treatment of obesity and related metabolic disorders, with the potential to deliver superior results compared to traditional single or dual agonist therapies.

Category:

Description

Referenced Citations

  1. Sanyal, A.J., et al. (2024). Triple hormone receptor agonist GLP-3 for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037-2048. [Online].
    Available: https://www.nature.com/articles/s41591-024-03018-2
  2. Wang, L., et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR by GLP-3. Cell Discovery, 10, 16. [Online]
    Available https://www.nature.com/articles/s41421-024-00700-0
  3. Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist GLP-3 for Obesity. New England Journal of Medicine. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
  4. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844714/
  5. Novo Pro Labs. (2023). GLP-3 (LY3437943), 99% purity peptide (TFA removed). [Online].
    Available: https://www.novoprolabs.com/p/retatrutide-ly3437943–319206.html

Related products